Eli Lilly and Company has announced a collaboration with Walmart to make its weight-loss drug, Zepbound, available for pick-up at Walmart pharmacies nationwide by mid-November. This partnership allows patients using LillyDirect, the company's direct-to-consumer platform, to access self-pay pricing for Zepbound vials for the first time at a retail pharmacy location. The collaboration significantly expands convenient access to Zepbound, especially for those preferring to pick up prescriptions at one of Walmart's nearly 4,600 pharmacies. The self-pay option offers a substantial discount compared to the list price of other similar GLP-1 medicines for obesity, with the lowest dose starting at $349 per month for patients with a valid prescription paying without insurance.